Prev: Diagnostic performance of anti-DFS70 antibodies in excluding systemic lupus erythematosus diagnosis: An updated systematic review and meta-analysisNext: Historical Perspective on Antinuclear Antibody Testing
Record 059 · Research · 2024
Evaluation of Progression From Preclinical to Systemic Autoimmune Rheumatic Disease: Novel Use of the European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria as an Outcome Measure
ACR Open Rheumatology · requested inclusion
“Two-year cohort assessed progression among asymptomatic and undifferentiated ANA-positive people; most did not progress over the short follow-up.”
Two-year cohort assessed progression among asymptomatic and undifferentiated ANA-positive people; most did not progress over the short follow-up. Limits noted in the record: Referred clinic cohort and two-year horizon limit generalization. A positive ANA is not a diagnosis. Claims in this record are not verified.
A positive ANA is not a diagnosis. Claims in this record are not verified.
source
- positive-ana
- progression-risk
- undifferentiated
Research
Also in this file
View all in file
Antinuclear antibody-negative systemic lupus erythematosus: How many patients and how to identify?22.34.E · Archives of Rheumatology
Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease23.35.E · BMC Rheumatology
High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease08.36.E · Lupus
Increasing Prevalence of Antinuclear Antibodies in the United States20.37.E · Arthritis & Rheumatology